Sponsor Overview
Explore verified public information about NanOlogy, LLC's expanded access programs, compassionate use policies, and patient eligibility pathways. This report aggregates official statements, independent research, and regulatory data to help patients, providers, and sponsors collaborate efficiently.
Unique references curated across 3 content categories.
ClinicalTrials.gov data sources power this status.
Dataset refreshed continuously through Right2Hope ETL pipelines.
Expanded Access Intelligence
Official Statements
Score contribution: 100 — 1 supporting sources.
“NanOlogy does not normally offer Expanded Access to our investigational drugs but rather encourages patients to speak with their physicians about eligibility to enroll in any of the NanOlogy clinical trials that may positively impact the patient’s illness. On an exceptional basis, however, NanOlogy may consider requests from US-licensed physicians for their patients who have exhausted all viable alternative therapies. Requests for Expanded Access must come from the treating physician via email to: info@nanology.us. NanOlogy will seek to respond to such requests within 10 business days.”
Past EAPs on ClinicalTrials.gov
Score contribution: 40 — 2 supporting sources.
Conditions: Locally Advanced Pancreatic Carcinoma, Prostate Cancer, Lung Cancer
Partner with Right2Hope
Right2Hope helps sponsors translate regulatory programs into actionable patient access pathways. Connect with our team to publish new programs, streamline intake workflows, or align with providers seeking compassionate use options.